Ipsogen Consolidates its Position in North America and Appoints Susan Hertzberg President
MARSEILLE, France, September 3 /PRNewswire/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and leukemia, today announces that Susan Hertzberg has been named President, Ipsogen Inc. and Vice President Corporate Business Development for Ipsogen SA. Ipsogen Inc. is the wholly owned US subsidiary of Ipsogen SA.
"We are excited to have Susan at Ipsogen. Her broad commercial experience and deep knowledge of the IVD and laboratory services sectors is a great advantage as we expand our presence in North American and around the world." CEO, Vincent Fert commented.
During her career, Ms. Hertzberg has been a strategic driver of growth and profitability and has held many executive positions. Immediately prior to joining Ipsogen, Ms. Hertzberg served as General Manager, Global Accounts at Abbott Diagnostics. Before that, she spent much of her career at Quest Diagnostics and progressed through many management and leadership positions, including, Vice President, Purchasing and Materials Management, and Vice President, Marketing.
Susan Hertzberg also has deep Payor experience which includes leading Ancillary Services Contracting at Oxford Health Care and Managed Care Contracting at Quest Diagnostics., In 1997, she received a MBA from Columbia University, NY.
About Ipsogen
Ipsogen, Cancer Profiler, develops and markets molecular diagnostic assays designed to map diseases and guide patients and clinicians' decisions along the complex therapeutic path.
With more than 60 references already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now also targeting breast cancer. Its initial goal will be to provide diagnostic information that remained unavailable until now. Ipsogen is also a partner of choice for biopharmaceutical companies committed to the development of 'companion diagnostic' tests.
Strengthened by its first-rate scientific, clinical and technological partnerships, in addition to its highly-skilled multidisciplinary team in France and the USA, Ipsogen is striving to become the leader in the molecular profiling of cancers. It is pursuing its development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.
Ipsogen employed 40 people as of April 30, 2008. Its headquarters are located in Marseilles, France. The company also has a subsidiary, Ipsogen Inc., in New Haven, CT, USA.
To learn more visit : http://www.ipsogen.com
CONTACT: Contacts: Ipsogen, +33(0)4-9129-3090 / +1(203)285-6170, Vincent
Fert, President and CEO - fert@ipsogen.com; ATCG Press, Corporate and
product information, Marielle Bricman - ipsogen@atcg-partners.com,
+33(0)4-9125-0785